Vaccination for glaucoma: Dream or reality?

Brain Research Bulletin

Volumn 62, Issue 6, 2004, Pages 481-484

  Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Degeneration; Glaucoma; Neuroprotection; Optic nerve; Protective autoimmunity

Indexed keywords

GLATIRAMER;

ACTIVE IMMUNIZATION; AUTOIMMUNITY; CONFERENCE PAPER; GLAUCOMA; HUMAN; IMMUNE RESPONSE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE INJURY; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

EID: 1342312497     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(03)00073-X     Document Type: Conference Paper

References (40)

1. Blaugrund E., Duvdevani R., Lavie V., Solomon A., Schwartz M. Disappearance of astrocytes and invasion of macrophages following crush injury of adult rodent optic nerves: implications for regeneration. Exp. Neurol. 118:1992;105-115.
2. Brubaker R.F. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am. J. Opthalmol. 121:1996;473-483.
3. Butovsky O., Hauben E., Schwartz M. Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7-2 (CD86) and prevention of cyst formation. Faseb. J. 15:2001;1065-1067.
4. Dreyer E.B., Grosskreutz C.L. Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Clin. Neurosci. 4:1997;270-273.
5. Dreyer E.B., Pan Z.H., Storm S., Lipton S.A. Greater sensitivity of larger retinal ganglion cells to NMDA-mediated cell death. Neuroreport. 5:1994;629-631.
6. Dreyer E.B., Zurakowski D., Schumer R.A., Podos S.M., Lipton S.A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 114:1996;299-305.
7. Faden A.I., Salzman S. Pharmacological strategies in CNS trauma. Trends Pharmacol. Sci. 13:1992;29-35.
8. Fisher J., Levkovitch-Verbin H., Schori H., Yoles E., Butovsky O., Kaye J.F.et al. Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J. Neurosci. 21:2001;136-142.
9. Gold R., Hartung H.P., Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci. 20:1997;399-404.
10. Hauben E., Agranov E., Gothilf A., Nevo U., Cohen A., Smirnov I.et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 108:2001;591-599.
11. Hauben E., Butovsky O., Nevo U., Yoles E., Moalem G., Agranov E.et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20:2000;6421-6430.
12. Hauben E., Nevo U., Yoles E., Moalem G., Agranov E., Mor F.et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet. 355:2000;286-287.
13. Hickey W.F., Hsu B.L., Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28:1991;254-260.
14. Hirschberg D.L., Moalem G., He J., Mor F., Cohen I.R., Schwartz M. Accumulation of passively transferred primed T cells independently of their antigen specificity following central nervous system trauma. J. Neuroimmunol. 89:1998;88-96.
15. Kaufman P.L., Gabelt B.T., Cynader M. Introductory comments on neuroprotection. Surv. Ophthalmol. 43(Suppl 1):1999;S89-S90.
16. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M.et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl. Acad. Sci. U.S.A. 97:2000;7446-7451.
17. Kipnis J., Yoles E., Schori H., Hauben E., Shaked I., Schwartz M. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J. Neurosci. 21:2001;4564-4571.
18. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A.et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
19. Levkovitch-Verbin H., Harris-Cerruti C., Groner Y., Wheeler L.A., Schwartz M., Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest. Ophthalmol. Vis. Sci. 41:2000;4169-4174.
20. Mizrahi T., Hauben E., Schwartz M. The tissue-specific self-pathogen is the protective self-antigen: The case of uveitis. J. Immunol. 169:2002;5971-5977.
21. Moalem G., Gdalyahu A., Shani Y., Otten U., Lazarovici P., Cohen I.R.et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J. Autoimmun. 15:2000;331-345.
22. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5:1999;49-55.
23. Moalem G., Monsonego A., Shani Y., Cohen I.R., Schwartz M. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. Faseb J. 13:1999;1207-1217.
24. Moalem G., Yoles E., Leibowitz-Amit R., Muller-Gilor S., Mor F., Cohen I.R.et al. Autoimmune T cells retard the loss of function in injured rat optic nerves. J. Neuroimmunol. 106:2000;189-197.
25. Quigley H.A., Nickells R.W., Kerrigan L.A., Pease M.E., Thibault D.J., Zack D.J. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36:1995;774-786.
26. Rowland L.P. Amyotrophic lateral sclerosis. Curr. Opin. Neurol. 7:1994;310-315.
27. Schori H., Kipnis J., Yoles E., WoldeMussie E., Ruiz G., Wheeler L.A.et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3398-3403.
28. M. Schwartz, Physiological approaches to neuroprotection. Boosting of protective autoimmunity. Surv. Ophthalmol. 45 (Suppl. 3) (2001) S256-S260 (discussion S273-S276).
29. Schwartz M., Belkin M., Yoles E., Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J. Glaucoma. 5:1996;427-432.
30. Schwartz M., Kipnis J. Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol. Med. 7:2001;252-258.
31. Schwartz M., Yoles E. Self-destructive and self-protective processes in the damaged optic nerve: implications for glaucoma. Invest. Ophthalmol. Vis. Sci. 41:2000;349-351.
32. Schwartz M., Yoles E., Levin L.A. 'Axogenic' and 'somagenic' neurodegenerative diseases: definitions and therapeutic implications. Mol. Med. Today. 5:1999;470-473.
33. Streilein J.W. Unraveling immune privilege. Science. 270:1995;1158-1159.
34. Weinreb R.N., Zangwill L.M. Imaging technologies for assessing neuroprotection in glaucomatous optic neuropathy. Eur. J. Ophthalmol. 9(Suppl 1):1999;S40-S43.
35. Yoles E., Friedmann I., Barouch R., Shani Y., Schwartz M. Self-protective mechanism awakened by glutamate in retinal ganglion cells. J. Neurotrauma. 18:2001;339-349.
36. Yoles E., Hauben E., Palgi O., Agranov E., Gothilf A., Cohen A.et al. Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 21:2001;3740-3748.
37. Yoles E., Muller S., Schwartz M. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J. Neurotrauma. 14:1997;665-675.
38. Yoles E., Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch. Ophthalmol. 116:1998;906-910.
39. Yoles E., Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv. Ophthalmol. 42:1998;367-372.
40. Yoles E., Wheeler L.A., Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. 40:1999;65-73.